Your browser doesn't support javascript.
loading
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity.
Gragnani, Laura; Visentini, Marcella; Lorini, Serena; Santini, Stefano Angelo; Lauletta, Gianfranco; Mazzaro, Cesare; Urraro, Teresa; Quartuccio, Luca; Cacciapaglia, Fabio; Ruscitti, Piero; Tavoni, Antonio; Marri, Silvia; Cusano, Giuseppina; Petraccia, Luisa; Naclerio, Caterina; Treppo, Elena; Del Frate, Giulia; Di Cola, Ilenia; Raimondo, Vincenzo; Scorpiniti, Daniela; Monti, Monica; Puccetti, Lorenzo; Elia, Giusy; Fallahi, Poupak; Basili, Stefania; Scarpato, Salvatore; Iannone, Florenzo; Casato, Milvia; Antonelli, Alessandro; Zignego, Anna Linda; Ferri, Clodoveo.
Afiliação
  • Gragnani L; MASVE Interdepartmental Hepatology Center, Department of Experimental and clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, Florence, Italy.
  • Visentini M; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Lorini S; MASVE Interdepartmental Hepatology Center, Department of Experimental and clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, Florence, Italy.
  • Santini SA; Department of Basic, Clinical, Intensive and Perioperative Biotechnological Sciences, Catholic University School of Medicine, Rome, Italy.
  • Lauletta G; Synlab Lazio, Roma, Italy.
  • Mazzaro C; Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro" Medical School, Bari, Italy.
  • Urraro T; Clinical Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
  • Quartuccio L; Rheumatology Unit, "M. Scarlato" Hospital, Scafati (SA), Italy.
  • Cacciapaglia F; Rheumatology Clinic Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy.
  • Ruscitti P; UO Reumatologia - Department of Precision and Regenerative Medicine-Ionian Area, University of Bari "Aldo Moro", Bari, Italy.
  • Tavoni A; Rheumatology Unit, Department of Biotechnological & Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Marri S; Clinical Immunology, University of Pisa, Pisa, Italy.
  • Cusano G; MASVE Interdepartmental Hepatology Center, Department of Experimental and clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, Florence, Italy.
  • Petraccia L; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Naclerio C; MASVE Interdepartmental Hepatology Center, Department of Experimental and clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, Florence, Italy.
  • Treppo E; Rheumatology Unit, "M. Scarlato" Hospital, Scafati (SA), Italy.
  • Del Frate G; Rheumatology Clinic Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy.
  • Di Cola I; Rheumatology Clinic Department of Medicine (DAME), ASUFC, University of Udine, Udine, Italy.
  • Raimondo V; Rheumatology Unit, Department of Biotechnological & Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Scorpiniti D; Rheumatology Clinic 'Madonna dello Scoglio' Cotronei, Crotone, Italy.
  • Monti M; Rheumatology Clinic 'Madonna dello Scoglio' Cotronei, Crotone, Italy.
  • Puccetti L; MASVE Interdepartmental Hepatology Center, Department of Experimental and clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, Florence, Italy.
  • Elia G; Clinical Immunology, University of Pisa, Pisa, Italy.
  • Fallahi P; Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, School of Medicine, Pisa, Italy.
  • Basili S; Department of Translational Research & New Technologies in Medicine and Surgery, University of Pisa, School of Medicine, Pisa, Italy.
  • Scarpato S; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Iannone F; Rheumatology Unit, "M. Scarlato" Hospital, Scafati (SA), Italy.
  • Casato M; UO Reumatologia - Department of Precision and Regenerative Medicine-Ionian Area, University of Bari "Aldo Moro", Bari, Italy.
  • Antonelli A; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Zignego AL; Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, School of Medicine, Pisa, Italy.
  • Ferri C; MASVE Interdepartmental Hepatology Center, Department of Experimental and clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, AOU Careggi, Florence, Italy.
J Clin Immunol ; 43(4): 680-691, 2023 05.
Article em En | MEDLINE | ID: mdl-36795264
ABSTRACT

PURPOSE:

Mixed cryoglobulinemia syndrome (MCs) is a rare immunoproliferative systemic disorder with cutaneous and multiple organ involvement. Our multicenter survey study aimed to investigate the prevalence and outcome of COVID-19 and the safety and immunogenicity of COVID-19 vaccines in a large MCs series.

METHODS:

The survey included 430 unselected MCs patients (130 M, 300 F; mean age 70 ± 10.96 years) consecutively collected at 11 Italian referral centers. Disease classification, clinico-serological assessment, COVID-19 tests, and vaccination immunogenicity were carried out according to current methodologies.

RESULTS:

A significantly higher prevalence of COVID-19 was found in MCs patients compared to Italian general population (11.9% vs 8.0%, p < 0.005), and the use of immunomodulators was associated to a higher risk to get infected (p = 0.0166). Moreover, higher mortality rate was recorded in MCs with COVID-19 compared to those without (p < 0.01). Patients' older age (≥ 60 years) correlated with worse COVID-19 outcomes. The 87% of patients underwent vaccination and 50% a booster dose. Of note, vaccine-related disease flares/worsening were significantly less frequent than those associated to COVID-19 (p = 0.0012). Impaired vaccination immunogenicity was observed in MCs patients compared to controls either after the first vaccination (p = 0.0039) and also after the booster dose (p = 0.05). Finally, some immunomodulators, namely, rituximab and glucocorticoids, hampered the vaccine-induced immunogenicity (p = 0.029).

CONCLUSIONS:

The present survey revealed an increased prevalence and morbidity of COVID-19 in MCs patients, as well an impaired immunogenicity even after booster vaccination with high rate of no response. Therefore, MCs can be included among frail populations at high risk of infection and severe COVID-19 manifestations, suggesting the need of a close monitoring and specific preventive/therapeutical measures during the ongoing pandemic.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Crioglobulinemia / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials / Diagnostic_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: J Clin Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Crioglobulinemia / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials / Diagnostic_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: J Clin Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália
...